According to PolyBeats monitoring, in the prediction market Polymarket, a Wise Money has invested $7.3k in the question "Will the Skin Cancer Vaccine receive FDA approval by 2028?" with an average buy probability of 61.1%. The current probability of "Yes" is 72.5%.
Brokie has also invested $7.3k, with the top relevant category in this market being Science, with a net profit of $22.9k. Brokie has participated in a total of 29 settled transactions in this category with a win rate of 21/29 (72%), including 9 transactions where the buy price was below $0.8 and the sell price was above $0.95. In the similar cost range ($0.651-$0.7), the median of Brokie's historical investment amount is $3.7k.
The cancer vaccine V940 developed by Moderna aims to train the immune system to identify and eliminate remaining cancer cells based on the specific mutations of the patient's tumor. On August 19, Moderna and Merck announced that their Phase III trial combining V940 and Merck's Keytruda showed that in over 1,100 high-risk melanoma patients, the combination therapy group had a longer time to recurrence or distant metastasis compared to Keytruda alone, meeting both key efficacy endpoints.
V940 already has a strong clinical and regulatory foundation. Long-term follow-up data from a Phase II trial released on June 1 showed that V940 combined with Keytruda reduced the risk of melanoma recurrence or death by 49% and the risk of distant metastasis or death by 59%; the project also received Breakthrough Therapy Designation from the FDA in 2023, and the Phase III melanoma trial has completed patient enrollment.
Even with substantial progress, from the announcement of Phase III results to full data submission, individualized manufacturing system review, FDA review, and final approval, there may still be additional data requirements or manufacturing quality specifications. The company's next step disclosed on August 19 is to release the complete data and engage with regulatory agencies, with no official FDA acceptance or clear approval timeline announced yet.
---------------------------------
See tomorrow, today. Follow @PolyBeatsEN to see the future earlier.
